Protocol Reference — MK-677 (Ibutamoren)

Conservative start

10 mg once daily for 2-4 weeks

Restores IGF-1 by approximately 52% with lower glycaemic and edema risk. Assess individual tolerance before escalating.

Standard clinical dose

25 mg once daily

The dose used in most Merck clinical trials. Maximises GH/IGF-1 elevation, fat-free mass, and sleep architecture effects.

Cycle length

8-12 weeks daily administration

Followed by a 4-week drug washout to reset insulin sensitivity and fluid balance.

Experimental pulsing

5 days on, 2 days off

Community protocol aimed at reducing insulin resistance via washout days. Not tested in clinical trials. Evidence is anecdotal.

Timing

Bedtime dosing is standard

Optimises Stage IV and REM sleep benefits while avoiding peak appetite spike during waking hours. Morning dosing is an alternative for those intentionally seeking appetite stimulation.